Lexicon Pharma (LXRX) Tops Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $1.42 -4.7%
Revenue Growth %: -79.9%
Financial Fact:
Consolidated net loss: -36.02M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: -79.9%
Financial Fact:
Consolidated net loss: -36.02M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of $0.01, $0.10 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $28.86 million versus the consensus estimate of $6.49 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Howard Hughes Holdings to join S&P SmallCap 600 on Oct. 28
- Tompkins Financial (TMP) Tops Q3 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
